, is a water-soluble amino acid that is derived entirely from dietary sources. It has received much attention as a therapeutic agent due to its anti-oxidant properties, and there are claims of preferential accumulation within high oxidative stress organs. Pre-eclampsia, a condition accompanied by increased oxidative stress, is one of the leading causes of maternal morbidity and mortality. Despite intense research efforts, its aetiologies remain somewhat unclear and there are still no effective treatment options. Clinical trials of the anti-oxidants vitamin C and vitamin E have proven largely ineffective with little improvement in clinical outcome or even a negative response. This could be explained in part by their inability to permeate the plasma and mitochondrial membranes and scavenge mitochondria-derived superoxide species, and for the former by the fact that it is actually a pro-oxidant in the presence of unliganded iron. ERG accumulates within tissues through the action of a specific organic cation transporter, SLC22A4 (previously referred to as OCTN1), which is possibly also expressed in mammalian mitochondria. Mitochondrial dysfunction has been implicated in a variety of vascular diseases including pre-eclampsia. This review discusses the use of ERG as a possibly mitochondrial-targeted antioxidant, focusing on its physical properties, potential mechanisms of action, safety profile and administration in relation to pregnancies complicated by pre-eclampsia.
Introduction
A disorder of late pregnancy, pre-eclampsia is the leading cause of maternal mortality accounting for 18% of maternal deaths worldwide (~77,000 deaths per year) [1] . Pre-eclampsia complicates 5% of nulliparous pregnancies and~4 million women per annum [2] . The disease aetiology is thought to involve poor immunoregulation causing deficient trophoblast invasion and spiral artery remodelling leading to defective placentation [3, 4] . Consequent, placental ischaemia leads to oxidative stress, with release of synctiotrophoblast debris into the maternal circulation provoking a systemic inflammatory immune response and release of plasma mediators: these include soluble fms-like tyrosine kinase-1 (sFLT), endoglin (sENG) and endothelin-1 (ET-1) [5] [6] [7] [8] . Because the vascular endothelium relies on pro-angiogenic factors, the release of anti-angiogenic factors by the placenta into the maternal circulation is a potential cause of the endothelial dysfunction observed in pre-eclampsia.
Currently, other than delivery, there is no effective treatment for pre-eclampsia, with clinicians limited to prophylactic treatment with aspirin and increased surveillance. Numerous publications over the past two decades have supported the hypothesis that oxidative damage is involved in the pathophysiology of pre-eclampsia [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . However, the results of clinical trials using classical small molecule anti-oxidants (vitamin C, vitamin E) have been largely disappointing, with little improvement in clinical outcome [20] . This possibly reflects these molecules' inability to penetrate to the central cellular source of reactive oxygen species -the mitochondria and its matrix. However not all reactive oxygen species are equally reactive/toxic (indeed peroxide and superoxide are even used as signalling molecules). In the case of ascorbate, it also probably reflects the fact that this is actually pro-oxidant and not anti-oxidant in the presence of unliganded iron, which can create the very damaging hydroxyl radicals via the Fenton reaction [21, 22] . This review focuses on a potential new therapeutic agent for pre-eclampsia: L-Ergothioneine (ERG). ERG is a naturally occurring anti-oxidant discovered over a century ago in the rye ergot. Recent evidence from cellular and animal models have shown that cells lacking ERG are more susceptible to oxidative stress [23] [24] [25] [26] [27] .
Ergothioneine
The unusual amino acid ergothioneine (also known as 2-mercaptohistidine trimethylbetaine; IUPAC name (2S)-3-(2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate) ( Fig. 1 ) was discovered by Charles Tanret in 1909 while investigating the ergot fungus, Claviceps purpurea that devastated rye grains [28] . It is a dietary watersoluble amino acid, derived from histidine, which is synthesised mainly by non-yeast fungi (especially basidiomycetes), actinobacteria [24] , methylotrophs [29] and cyanobacteria [30] . Numerous physiological roles of ERG have been proposed including cation chelation (Cu 2+ in particular) [31, 32] , immune regulation, regulation of gene expression and most widely as a direct anti-oxidant due to its preferential concentration in high O 2 stress organs: liver, kidneys, erythrocytes, eye lens and seminal fluid [24, 26, . Despite ERG's high concentration and ubiquitous presence, all mammalian ERG is derived from dietary sources with typical whole blood concentrations of 66 ± 2.2 µmol/L [54] ( Table 1) . To date, only one study has investigated the pharmacokinetics of ERG administration in human subjects [23] . In this study, healthy human subjects were administered either a 5 mg or 25 mg dose every morning for one week. ERG was rapidly absorbed and retained within the tissue/plasma with relatively low urinary excretion ( < 4% of administered dose). Furthermore, a decrease in markers of oxidative stress was observed, but these changes did not reach significance. There is retrospective evidence to suggest patients with features of metabolic syndrome who consume at least 100 g of Agaricus bisporus (white button mushrooms, a major source of ERG) have increased antioxidant biomarkers compared to controls, with no change in lipid peroxidation markers [55] . The rapid uptake and retention of ERG in combination with the above data suggests that the amino acid has an important physiological function but perhaps only under conditions of oxidative stress. Fig. 2 gives an overview of this article in the form of a 'mind map' [56] . Fig. 1 . Structure of thione-thiol tautomers of ergothioneine (2-mercaptohistidine trimethylbetaine) (A). In solution at physiological pH, ergothioneine exists predominantly in the thione rather than the thiol form, which ensures its resistance to autoxidation. Ergothioneine shares structural similiarities with (B) hercynine, (C) methimazole and (D) stachydrine (proline betaine). 
SLC22A4 (previously OCTN1): The ergothioneine transporter
Despite a widespread belief (including in textbooks) that molecules can pass easily through the bilayer portion of biological membranes, this is not the case and specific transporters are required [57] [58] [59] [60] [61] . ERG crosses the intestinal epithelium via the "organic cation transporter, novel, type 1" (OCTN1), now known as solute carrier family 22, member 4 (SLC22A4) [62] . Organic cation transporters function primarily in the elimination of drugs in tissues such as the kidney (especially), intestine, liver and placenta by mechanisms dependent on or independent of sodium-gradient, pH or membrane potential [63] . SLC22A4 had previously been considered to be a carnitine transporter, but Gründemann and colleagues recognised that the observed rates were really very low [64] . Under these circumstances, untargeted metabolomics is the best strategy [64] [65] [66] [67] [68] . Using such an approach, comparing HEK293 cells with or without extra cloned SLC22A4, the authors determined that ERG was transported~100 times quicker than was carnitine, and thus was the best candidate to date for the 'natural' substrate of SLC22A4. This sodium-dependent transporter has a high affinity for ERG (K m = 21 µM) relative to the structurally similar methimazole and hercynine respectively [64] (see Fig. 1 ). It was concentrated some 180-fold relative to the external concentration, which possibly implies a stoichiometry of two Na + per ergothioneine transported, although the intracellular distribution was not determined [64] . The discovery by Gründemann, Schömig and colleagues [64, 69] that the actual substrate for this transporter is in fact an exogenous compound was also a landmark piece of work that drew attention to the likelihood that the majority of 'natural' substrates for such transporters are indeed probably plant and microbial natural products [70] . In humans, the expression of SLC22A4 has been observed in numerous organs, with the highest levels said to be in bone marrow, small intestine, foetal liver, kidney, cerebellum and spinal cord [33, 64, 71] . Fig. 3 shows its absolute transcriptome expression levels in 56 cell lines (using data from [72] ). Mitochondrial transporters are designated as members of the SLC25 family [73, 74] . It has also been claimed that SLC22A4, which is not a member of the SLC25 family, is expressed in mitochondria [75] . This would be both unusual and important if so, and thus we examine this claim in some detail.
Evidence for mitochondrial distribution of SLC22A4
Although the fact that SLC22A4 is a concentrative ERG transporter is well established from the studies of Gründemann and colleagues, where the transporter was (presumably) expressed in the plasma membrane, its normal localisation is rather less clear. Similarly, although SLC22A4 is considered to be relatively specific for ERG, we know nothing about other transporters, especially the many promiscuous cation transporters and their expression, for which ERG might also be a or the substrate. At least the first Gründemann et al. paper definitely showed that it was concentrated relative to its levels in the incubation medium, but they did not perform subcellular localisation studies. Several papers have focussed on the mitochondrial localisation and/or accumulation of ERG [75] [76] [77] [78] . The first two are those of Lamhomwah and colleagues [75, 76] and of Kawano and colleagues [78] . The latter was an early paper and used radioisotopes to study the subcellular distribution of labelled ERG; 10 min after injection approximately 15% of the label was associated with a crude mitochondrial fraction, but although the tables refer to mitochondrial localisation, the authors referred in the text (with no evidence either way) to "transfer of radioactivity to the mitochondria which probably represents the distribution of 3 H or 3 H 2 O formed by degradation". The papers of Lamhomwah and Xuan based their evidence mainly on the use of antibodies, which are notoriously unreliable, and the uptake studies used carnitine, a very poor substrate for OCTN1 [75] [76] [77] 79, 80] . While ERG is uncharged at neutral pH, it is probably fair to say that the question of whether ERG is in fact concentrated in mitochondria is [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] actually rather open, and if it does which transporters were used to get and/or accumulate it there. Some uptake studies using purified mitochondria would seem to be in order here. Similarly, strategies that seek transporters whose expression levels vary cytotoxicity under oxidative stress in the presence of ERG (for example) ought to be able to find other transporter candidates [81, 82] . Consistent with the difficulty of obtaining good antibodies for SLCs, present data from the human protein atlas (http://proteinatlas.org/) refer to SLC22A4 as membrane-associated, but describe its expression as being in the nucleoplasm or cytoplasm. A mainly mitochondrial expression might also suggest coexpression with other mitochondrial transporters (members of the SLC25 family) or mitochondrial reference genes such as the cytochrome oxidase I subunit [83] but there do not seem to be any standout correlations (Fig. 3) . This said, the expression of very few SLC25 genes seems to correlate with that of the cytochrome oxidase subunit either (DBK, unpublished observations).
In vitro and ex vivo evidence of an anti-oxidant role for ergothioneine
Numerous studies have found evidence reflecting the anti-oxidant role of ERG in vitro [32, 33, 42, 43, 46, 48, 51, 53, [84] [85] [86] . Some evidence from animal studies suggests ERG protects against tissue damage induced by ischaemia-reperfusion injury in liver, heart and intestine [37, 50, 85] . It has been shown to protect PC12 cells from H 2 O 2 -induced apoptosis, arachidonic acid from lipid peroxidation, and its anti-oxidant properties have even been utilised by the food industry to prevent the discolouration of red meat and preserve crustaceans post-harvest [36, 39, 86, 87] . Genetic studies silencing SLC22A4 expression in cultured erythroid cells have observed decreased uptake of ERG leading to apoptosis [88] . Furthermore, a reduction in HeLa cells' ERG concentration caused significant increases in oxidative burden on mitochondrial components, measured through increased protein carbonylation (biomarker of oxidative damage to proteins) [89] and extracellular mitochondrial DNA (biomarker of mitochondrial dysfunction) [26] . Although the anti-oxidant role of ergothioneine has been well established in vitro, fewer studies have demonstrated protective effects in vivo.
In vivo evidence of anti-oxidant role
There is some in vivo evidence to suggest ERG acts as an anti-oxidant in animal models of lung injury [90] , hepatorenal dysfunction [40] , and ischaemia/reperfusion injury to the liver [37] and small intestine [50] . Studies using SLC22A4 -/-mice show a deficiency of ERG in both serum and tissue. This is associated with a greater susceptibility to intestinal inflammation under an ischaemia and re-perfusion model, which is known to produce various reactive oxygen species [25] . Through a variety of proposed mechanisms, ERG has been shown to act as a neuroprotectant against cisplatin [51] , beta-amyloid [91] and D-galactose toxicity [52] in mice, and of NMDA excitotoxicity in rats [47] . While some evidence exists of ERG's protective effects in vivo, most studies have been used models of severe oxidative stress, and the presently available data do not indicate if (or the extent to which) ERG acts as an anti-oxidant under normal or just moderately stressful circumstances (Table 2) .
Ergothioneine and human disease
Various publications over the past two decades have suggested a role for ERG (or an inadequacy of it) in chronic inflammatory disease [104] [105] [106] [107] , neurodegeneration [108] , acute lung injury [49] and cardiovascular disease [44, 85, 109] . Mutations in the SLC22A4 gene have been implicated in rheumatoid arthritis (RA) [104, 105] and Crohn's disease [106, 107] . Furthermore, ERG levels are increased in the erythrocytes of RA patients [104] and the inflamed intestinal mucosa of Crohn's patients, both of which corresponded to increase in SLC22A4 mRNA expression [71] . It has been postulated that the increased ERG uptake stimulates inflammation by promoting immune cell survival through inhibiting cell death mechanisms ERG [33, 110] . On the other hand, some studies indicate the elevated ERG levels may be secondary, i.e. a response, to cytokine-mediated upregulation of SLC22A4. Both TNF-α and IL-1β have been shown to increase SLC22A4 expression [71, 111] . Therefore, the elevated ERG in chronic inflammatory conditions may (indeed is logically more likely to) be a cellular response to inflammation rather than a cause underlying disease pathogenesis.
Conversely, a cohort of Japanese Crohn's disease patients manifested a decreased serum ERG concentration compared to healthy controls [25] . The authors of this study linked their observations to SLC22A4 gene knockout mice where decreased ERG predisposed to intestinal inflammation suggesting ERG may play a role in alleviating intestinal inflammation [25] . Interestingly, patients with ulcerative colitis showed no difference in erythrocyte ERG concentrations when compared to healthy controls. Decreased ERG concentrations have also been observed in the erythrocytes of patients with chronic myeloid leukaemia [112] , RA [113] , Parkinson's disease [108] and in the eye lens of cataract patients [114] . These data support the involvement of ERG and its homeostasis in the pathophysiology of certain diseases.
Proposed mechanisms of action
Several mechanisms for the protective effects of ergothioneine have been proposed, which we have grouped into five main categories and summarised in Fig. 4 . First, it acts as a direct scavenger of reactive oxygen species and related molecules: hydroxyl radicals (•OH) [42, 86, 115] , hypochlorous acid (HOCl) [86] , peroxynitrite (ONOO -) [116] and ferrylmyoglobin (reactive oxygen species formed when myoglobin reacts with H 2 O 2 ) [85] . In addition to preventing DNA damage and apoptosis, scavenging may prevent oxidative stress-induced alterations in gene expression (e.g. cytokine production). Indeed, ERG has been shown to decrease IL-1β-stimulated monocyte adhesion in human artery endothelial cells [46] . The mechanism of protection is thought to be a reduction in ferrylmyoglobin, as evidenced through decreased tissue malondialdehyde and changes in NF-κB activation [37, [48] [49] [50] . Furthermore, in human umbilical vein endothelial cells (HUVEC), ERG decreased oxidised-LDL-induced apoptosis by inhibiting Bax activation, Bcl-2 downregulation and caspase-3 activity elicited by oxidised LDL [117] . Secondly, ERG can form complexes with divalent metal cations, the most stable of which is with copper [31] [32] [33] . Cell-free experiments indicate that ERG chelation of metal ions protects both DNA and protein against copper-induced oxidative damage [32, 86] . In human studies, high levels of ERG in semen prevented Cu 2+ inhibition of sperm motility [118] . Furthermore, in animal models of ischaemia/reperfusion injury, iron and copper chelation has been shown to decrease reactive oxygen species production, which supports this alternative mechanism of ERG-mediated cytoprotection [22, [119] [120] [121] [122] . Thirdly, ERG-mediated upregulation of proteins involved in antioxidant cellular pathways has been observed, including Nrf2 [43] , Hsp70 [50] , superoxide dismutase (SOD), GSH reductase and catalase [44] . Conversely, a downregulation of the pro-oxidant enzyme NADPH oxidase has been observed with ERG treatment in endothelial cells [44] .
Fourthly, ERG absorbs light in the ultraviolet range [123] . This physical property may account, at least in part, for its observed cytoprotective effects against UV-induced damage and cell death [34, 35, 41, 124] . In keratinocytes exposed to ultraviolet-radiation, ERG was shown to decrease caspase-9 activity significantly, and concomitantly to increase cell survival [45, 124] . However, much skin damage is mediated through the generation of reactive oxygen species, so the extent to which these results can also be explained by direct superoxide scavenging is unclear [125] .
Finally, ERG may have a role in cellular repair mechanisms and cellular proliferation. Nakamura et al. showed that a decreased [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] accumulation of ERG in K562 cells was accompanied by significantly decreased cell growth compared to controls [88] . The authors of this study attribute their findings to inhibition of the cell cycle and apoptosis induction in ERG deficient cells. Moreover, it was reported that ERG prevents H 2 O 2 -induced apoptosis via inhibition of the p38-MAP kinase pathway, which is known to be involved in inflammation and apoptosis [39, 126] .
Oxidative stress in pre-eclampsia
Oxidative stress occurs when the production of reactive oxygen species outweighs the biological system's anti-oxidant defences. The two-step aetiological model of pre-eclampsia proposed by Redman suggests that poor placentation in the first half of pregnancy precedes oxidative stress in the second half of pregnancy [18, 127, 128] . Excessive oxidative stress is thought to be involved in the pathophysiology of many pregnancy-related disorders including miscarriage and foetalgrowth restriction (FGR) as well as pre-eclampsia [10] . It is a general accompaniment to all chronic, inflammatory diseases, as are iron dysregulation [22, 122, 129] and coagulopathies [130] [131] [132] [133] [134] [135] , probably driven by dormant microbes that can generate inflammagens [3, 133, [136] [137] [138] [139] [140] . From a systems biology point of view, a common cause of the production of reactive oxygen species is partial reduction of O 2 by over-reduced elements of the mitochondrial respiratory chain, especially within complexes I and III [122] . One cause of this can be substrate over-supply; another is hypoxia. Hypoxia is also a potent stimulus of xanthine oxidase, an important source of peroxide generation, which is highly expressed in synctiotrophoblasts and villous stromal cells [141] . Furthermore, several reports have observed higher levels of markers of oxidative stress (F 2 -isoprostanes, nitrotyrosine and 4-hydroxynonenal staining) in placentas from pre-eclamptic pregnancies compared to those from uncomplicated pregnancies [142] [143] [144] [145] . Recent work by Hung et al. supports placental hypoperfusion and aponecrotic processes as instigators of placental oxidative stress, with subsequent immature placental release of syncytiotrophoblast debris into maternal circulation [146] . An increased exposure to such particles in pre-eclampsia has been linked to activation of neutrophils in the maternal circulation, which may contribute to maternal endothelial dysfunction [147] . The hallmarks of pre-eclampsia are hypertension and proteinuria, and both hypertension and proteinuria implicate the endothelium as a major target of the pre-eclampsia. Hypertension in pre-eclampsia is characterised by peripheral vasoconstriction and decreased arterial compliance [148, 149] . Proteinuria is characterised by pathognomonic renal lesion known as glomerular endotheliosis, in which the endothelial cells of the glomerulus swell and endothelial fenestrations are lost. [150] .
In recent years, defective placental anti-oxidant capacity in preeclampsia, reflected by either the expression/activity of anti-oxidant enzymes or by levels of vitamin E, has been proposed as one of the earliest events in pre-eclampsia [151] [152] [153] . Indeed, uncomplicated pregnancy is recognised as a state of oxidative stress even under normal circumstances [154] . By 10-12 weeks' gestation the increased maternal blood flow to the placenta causes a local increase in oxygen and elevation in the activity of anti-oxidant enzymes [155] . The loss of mitigating systems normalising placental oxidative stress may lead to the generation of pathogenic factors, maternal endothelial activation and subsequent vascular dysfunction [5] . Jauniaux et al. have suggested that the impaired anti-oxidant response and subsequent oxidative stress may lead to trophoblast degeneration possibly contributes to impaired trophoblast invasion with diminished remodelling of the spiral arteries [155] . Defective placentation resulting from impaired invasion of maternal myometrium by endovascular trophoblasts results in an exaggerated state of oxidative stress in pre-eclampsia which may further hinder remodelling of myometrial spiral arteries (Fig. 5) .
During healthy pregnancy, spiral arteries in the maternal myometrium are remodeled by invading endovascular trophoblasts (originating in the anchoring villi of the foetal portion of the placenta). Invading endovascular cytotrophoblasts modify the spiral arteries 
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Free Radical Biology and Medicine 117 (2018) [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] resulting in the development of a high-flow, low-resistant vascular system capable of implementing sufficient perfusion to sustain the developing fetus. In pre-eclampsia, there is substantial evidence for shallow trophoblast invasion of uterine vasculature, with only superficial decidual regions of the vascular wall undergoing transformation resulting in high pressure blood-flow mediated placental damage.
Mitochondrial dysfunction in pre-eclampsia
There are several sources of reactive oxygen species within a cell. However the mitochondria, as hosts of the electron transport chain (ETC), are the predominant producers. In the last decade, there has been a great deal of interest in the role of mitochondria in human disease [156] . Numerous publications have observed a role for mitochondrial reactive oxygen species in atherosclerosis, diabetic vascular dysfunction, pulmonary artery hypertension and essential hypertension [156] . It has been proposed that mitochondrial reactive oxygen species generated by exposure to cardiovascular risk factors (smoking, hyperglycaemia, ageing, hyperlipidaemia and high dietary salt) result in endothelial dysfunction leading to vascular remodelling through inflammation, oxidative stress and apoptosis [156] . In terms of preeclampsia, there is evidence implicating mitochondrial dysfunction in its underlying pathophysiology [157] . Early studies have observed increased mitochondrial lipid peroxidation and enhanced susceptibility to oxidative damage in the placenta of pregnancies complicated by preeclampsia [158] .
Placental mitochondria
The placenta, a highly metabolically active organ, requires great numbers of functional mitochondria to meet the metabolic demands of pregnancy. A balance between mitochondrial fusion and fission is necessary to maintain the appropriate morphology, number and function [55, 159] . Fusion and fission targets are known to be regulated by peroxisome proliferation-activated receptor γ co-activator 1α (PGC-1α) [160, 161] . PGC-1α activity linked to PPARs, RXR and ERRα have been related with the expression of several mitochondrial proteins such as UCP, NRF1, NRF2, DRP1, FIS1, MFN2 [162] [163] [164] [165] [166] . In addition, PGC-1α binds to and co-activates NRF-1 increasing its transcriptional activity on target genes including mitochondrial transcription factor A (mtTFA). mtTFA subsequently translocates into the mitochondria and directly activates transcription and replication of mtDNA. Previous data from our laboratory found that pregnant rats treated with a PPAR-γ specific antagonist, T0070907, developed key features of pre-eclampsia, including elevated mean arterial blood pressure, proteinuria, endothelial dysfunction, reduced pup weight, and increased platelet aggregation [167] . While the authors of this study postulate alterations in trophoblast differentiation as a potential mechanism, it is possible that mitochondrial dysfunction and impairment in bioenergetic supply caused by PPAR-γ antagonism led to detrimental effects on placentation. Furthermore, a reduction in the placental expression of PPAR-γ activators has been demonstrated in some women who develop severe preeclampsia [168] , and significantly higher PPAR-γ DNA binding activity has been demonstrated in placentas from women with both IUGR and pre-eclampsia [169] . The increased circulating PPAR-γ activators in pregnancy have yet to be identified. In the study cited, serum extracts from each normal pregnancy and pre-eclampsia were used to treat JEG-3 cells that had been transfected with plasmids containing cDNA for PPAR-γ and the PPAR DNA response elements (PPRE) as well as a control vector (pRL-TK). Serum extracts from women with severe earlyonset pre-eclampsia showed a reduction in activation of PPAR-γ of more than 60% compared with that in serum extracts of normal pregnant women (P = 0.02). Similarly, severe late-onset pre-eclampsia showed a significant, albeit lesser (55%), decrease in PPAR-γ activation relative to matched normal pregnant controls (P = 0.05). Decreased PPARγ activation was not observed in mild pre-eclampsia (P = 0.42). Furthermore, previous data using epithelial cells of the renal proximal tubules, found oxidative stress-induced alterations in PPAR-γ (decreased expression, increased phosphorylation and decreased PGC-1α) in association with mitochondrial destabilisation leading to cellular apoptosis [170] . This suggests that mitochondrial pathology may be involved in both the first-step (poor placentation) and second-step (oxidative stress) of pre-eclampsia (Fig. 6) .
During stage 1, reduced oxidant capacity in pre-eclampsia may lead to alterations in PPAR-γ signalling. The resultant defects in mitochondrial biogenesis and dynamics impairs placentation with subsequent oxidative stress. During stage 2, the release of placental components into maternal circulation increases mitochondrial reactive oxygen species causing endothelial dysfunction. Overactivation of the maternal endothelium is thought to underlie its clinical manifestations which may be facilitated through loss of endothelial protective mechanisms and cell signalling checkpoints. These two stages may be linked, 
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Endothelial mitochondria
Mitochondrial content in endothelial cells is modest [156] . In vascular endothelium, the mitochondria are more likely to act as much as signalling organelles than as engines for cellular metabolism [156, 171] . Levels of mitochondrial reactive oxygen species are now recognised as potential redox signals in inflammatory environments [172] . Our group has recently detected increased levels of plasma-induced mitochondrial reactive oxygen species production in HUVECs incubated with plasma from women with pre-eclampsia compared with matched controls and non-pregnant controls. Furthermore, treatment of these cells with the mitochondria-specific anti-oxidant MitoTempo protected against hydrogen peroxide-induced cell death [5] . MitoTempo has been shown to accumulate within the mitochondria of endothelial cells increasing mitochondrial O 2 -dismutation while not affecting cytoplasmic dismutation i.e. it is a mitochondria-specific superoxide dismutase [173] . This suggests plasma mediators produced in pre-eclampsia influence mitochondrial reactive oxygen species production in the vascular endothelium, which may contribute to dysfunction and apoptosis. Indeed, the administration of soluble fms-like tyrosine kinase-1 (sFlt-1), a potent plasma mediator in pre-eclampsia, disrupted maximal mitochondrial respiration and caused a concentration-dependent decrease in mitochondrial membrane potential in human aortic endothelial cells [174] . These results argue that sFlt-1 is a pathogenic mediator that is at least partly responsible for the endothelial dysfunction observed in preeclampsia. Furthermore, a study by Zsengellér and colleagues [175] observed an inverse correlation between mitochondrial ETC cytochrome c oxidase enzyme activity and placental expression of sFlt-1 implying that its pathogenic role may potentially be mediated through mitochondrial dysfunction [175] . However, the contribution of mitochondrial reactive oxygen species to said dysfunction remains to be fully elucidated.
The immunostimulatory role of mitochondria
Pre-eclampsia is associated with a substantial increase in cell-free foetal DNA in maternal plasma [176] . Oxidative damage and inflammation are intimately linked, and both are recognised as deleterious mediators in the pathogenesis of pre-eclampsia. Both placentaderived cell-free DNA and mtDNA are thought to act as damage associated molecular patterns (DAMPs) which activate the innate immune system through Toll-like receptor 9 (TLR-9) expressed on antigen presenting cells, in particular neutrophils (Fig. 7) [177] . Neutrophil extracellular traps (NETs), seen as a marker of circulating neutrophil activation, are increased in the placentas of pre-eclamptic pregnancies, and are proposed to contribute significantly to the underlying pathology of pre-eclampsia [178] . The resultant neutrophil response may lead to over-activation of the maternal endothelium. Furthermore, activation of TLR-9 through injection of CpG oligonucleotides to pregnant rats induced pre-eclampsia-like symptoms, an observation which was not observed in non-pregnant rats [179] . Finally, pre-eclamptic plasmainduced mitochondrial reactive oxygen species production in HUVECs was shown to correlate with increased TLR-9 mRNA expression in treated cells [5] . The above data suggest that mitochondrial DAMPs contribute to the innate inflammatory immune response in preeclampsia.
The prevalence of pre-eclampsia in patients suffering from antiphosphololipid syndrome is massively enhanced over almost any other [180] . In this regard, it is at least worth noting that of mammalian lipids, cardiolipin, the chief antigen of phospholipids, is essentially confined to mitochondria [181] (It is also a major lipid in dormant bacteria [182] ).
Mitochondrial DNA (mtDNA) and mitochondrial reactive oxygen species represents a mitochondrial damage associated molecular patterns (DAMPs) and are often liberated as signal of mitochondrial dysfunction. Mitochondria are evolutionary endosymbionts that originated 
R.N. Kerley et al.
Free Radical Biology and Medicine 117 (2018) [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] from bacteria; hence, they express molecular motifs that can activate innate immunity. Mitochondrial DAMPs bind specific pattern-recognition receptors, including TLR-9 (binds mtDNA) and trigger an innate immune response, initially in neutrophils.
Ergothioneine as a viable therapeutic agent
The existence of a specific transporter for ERG suggests it has specific physiological roles. Furthermore, certain polymorphisms in the gene which encodes SLC22A4 show an association with various inflammatory and metabolic diseases [105, 106, 183, 184] . Limited evidence exists regarding the safety profile of ERG, but the available evidence is encouraging [23, 98, 101] . The ability of ERG to accumulate in 'high oxidative stress' organs makes it a promising target in the search for a viable therapeutic agent in pre-eclampsia [33, 71] .
Safety profile
To date, only one study has investigated the pharmacokinetics and safety profile of pure ERG administration in human subjects [23] . This study of healthy volunteers reported no adverse effects following either a 5 mg or 25 mg dose taken every morning for one week. ERG was rapidly absorbed and retained within the tissue/plasma with relatively low urinary excretion ( < 4% of administered dose). Furthermore, a decrease in markers of oxidative stress was observed, but these changes did not reach significance. There is retrospective evidence to suggest patients with features of metabolic syndrome who consume at least 100 g of Agaricus bisporus (white button mushrooms, a major source of ERG) have increased antioxidant biomarkers compared to controls, with no change in lipid peroxidation markers [55] . The rapid uptake and retention of ERG in combination with the above data suggests that the amino acid has an important physiological function but perhaps only under conditions of oxidative stress.
In animal studies, a 90-day administration at dose levels of 0, 400, 800 and 1600 mg per kg of body weight per day in Sprague Dawley rats showed no adverse clinical, behavioural or histopathological changes [101] . This study also looked for mutagenicity in a bacterial reverse mutation assay and found that ERG is not mutagenic to plate concentrations of 5000 µg mL -1 .
Use in pregnancy
Studies investigating reproductive safety using Sprague Dawley rats found ERG was well tolerated without adverse effects on their tested reproductive parameters: number of mating days, pregnancy rates, gestation length, pre-and post-implantation losses, number of pups delivered, pup viability index or litter parameters (size, clinical signs, body weight, sex ratio) [98] . Furthermore, supplementation of diabetic pregnant rats with ERG for the first 11.5 days of gestation decreased the rate of embryo malformations to that of non-diabetic controls [95] . The supplement had no effect on blood glucose levels but may inhibit glucose-mediated reactive oxygen species-dependent embryo malformations. A further study found that the enrichment of bovine in vitro produced (IVP) embryos with 0.1 mM ERG improved embryo quality as indicated by the lower rate of cell death, and an increased percentage of blastocysts with the most physiological inner cell mass: total cells ratio (20-40%) [53] . These data suggest ERG supplementation in pregnancy is safe and may prevent embryo malformations induced by oxidative stress. Given the established benefit of dietary supplementation with folic acid around the time of conception, ERG may best be utilised as a prenatal supplement [185, 186] . Maintaining a high tissue concentration of the anti-oxidant prior to conception may reduce circulating oxidative stressors as well increase the amount of plasma ERG available to cross the placenta into foetal tissue. In recent years, several academic societies have recommended a higher dose of folic acid for diabetic pregnant women in the periconceptual period due to their increased risk of congenital malformations [187] [188] [189] [190] [191] . Given the above evidence ERG may be prove most beneficial in the periconceptual period.
Use in pre-eclampsia
The available data suggest that erythrocyte ERG levels are increased in pre-eclampsia [192] . This could be explained by increased SLC22A4 expression in response to inflammatory cytokines produced in preeclampsia [26] . This novel stress response has been observed in the liver tissue of an animal model of non-alcoholic fatty liver disease [38] . This response may be a protective mechanism used to reduce oxidative stress and delay tissue injury. Preliminary data from our laboratory have found that placental SLC22A4 levels are increased in a reduced uterine placental perfusion (RUPP) model of pre-eclampsia (unpublished). These data suggest ERG levels could potentially be used as a biomarker of oxidative stress. One study measured ERG concentrations in the amniotic fluid of pregnant sheep after natural mating and transfer of vitrified/thawed IVP embryos [54] . Interestingly, ERG concentrations were significantly higher in IVP pregnancies, with no significant differences in gestational age. Thus, in IVP pregnancies, the higher ERG concentrations may be an indicator of a more severe inflammatory state compared to that following natural mating (Table 1) .
In terms of its therapeutic use, as discussed above, there are unsubstantiated claims that the compound is distributed in mitochondria, with the expression of SLC22A4 also observed in mammalian cell lines [75, 78] . Furthermore, localisation of OCTN1 in adult murine brain suggests a potential role in cerebral bioenergetics and the authors propose a predicted clinical phenotype for OCTN deficiency that may be analogous to the clinical phenotype of the deficient mitochondrial carnitine transporter, carnitine acylcarnitine translocase. [75] . Currently, despite the paucity of a defined role for ERG in mediating mitochondrial metabolism or even its accumulation in this bio-organelle, its strong anti-oxidant effects suggest that ERG should have a substantial effect on mitochondrial function. Hence, if mitochondrial dysfunction and subsequent release of mitochondrial reactive oxygen species are involved in the first stage of pre-eclampsia it is possible that prenatal supplementation with ERG may mitigate oxidative damage involved in poor placentation. This argument gains further momentum when considering the changes in serum ERG concentration throughout life [193] . The compound passes from mother to pup in breast milk with its erythrocyte concentration in the neonate shown to double within the first 3 months [193] . Additionally, ERG concentration in human red blood cells increases from one to ten years with a steady decrease till fifty years after which it stabilises [194] . Therefore, ERG levels decrease steadily throughout the reproductive years. Regardless of any involvement in placentation, there is evidence to suggest that its anti-oxidant activity reduces plasma-mediator induced mitochondrial reactive oxygen species production which may protect against maternal endothelial cell dysfunction [5] . Furthermore, ERG is known to cross the blood brain barrier (BBB), and given its established neuroprotective effects it may have protective or even preventative role in the development of eclampsia [195] [196] [197] .
Mechanism of action in pre-eclampsia
As outlined in Fig. 4 , ERG has been shown to exhibit its anti-oxidant effects through a number of mechanisms both direct and indirect. In the serum of pre-eclamptic women there is an increase in free iron due to haemolysis caused by destruction of RBCs as a result of vasospasm or abnormal endothelial cell erythrocyte interactions [198] . Reactive oxygen species generated from increased serum free iron has been implicated in the pathogenesis of pre-eclampsia [198] [199] [200] [201] . Iron is particularly abundant in the placenta and may arise in the ischaemic placenta by destruction of red blood cells from thrombotic, necrotic and haemorrhagic areas [202, 203] . This serum free iron has been shown to correlate with lipid peroxides in serum and placental tissue [204] . The R.N. Kerley et al. Free Radical Biology and Medicine 117 (2018) [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] authors of this study concluded that ischaemic placental tissue may be a primary source of potentially toxic iron in pre-eclampsia and the released iron species may contribute to lipid peroxidation and endothelial cell injury. Thus, in addition to its direct reactive oxygen species scavenging, ERG may uniquely decrease iron-induced oxidative stress through transition metal chelation in pre-eclampsia.
5.5. Can Ergothioneine reach plasma levels necessary for the direct antioxidant activity well described in vitro?
With regard to human endothelial cells, 1 nM of ERG was added to cells which produced an increase in anti-oxidant enzymes (catalase, glutathione reductase and superoxide dismutase) and a reduction in pro-oxidant NADPH oxidase 1 [92] . As far as plasma concentrations achieved post-treatment with ERG, most in vivo studies do not report the plasma levels achieved with a particular dosage regime. A study by Kato et al. [25] observed wild type mice achieved an ERG level of 16.5 ± 0.6 μg/mL on a regular diet while SLC22A4 knock-out mice achieved a plasma level < 2.13 μg/mL which was associated with an increased susceptibility to intestinal inflammation [25] . However, no focus was placed on the mechanism of action. In a study of patients with metabolic syndrome, eating 100 g of white button mushrooms per day (3.2 mg of ERG per day) achieved a mean plasma level of 677 ng/mL [100] . The increased levels of ERG (doubling over 16 weeks) was associated with an increase in the anti-oxidant biomarker ORAC (oxygen radical absorption capacity). No difference was observed between lipid peroxidation biomarkers. Finally, Deiana et al. [40] detected ERG in the tissue of rats following oral supplementation (70 mg/kg/d). After one week of treatment the levels reported were 0.66 μg/mg tissue in the kidney and 1.33 μg/mg tissue in the liver. ERG significantly reduced kidney and liver levels of conjugated dienes and conserved the concentrations of α-tocopherol and glutathione in the kidney and liver in the ferric-nitrilotriacetate/ERG treated rats.
Conclusion
ERG has come to prominence as an unusual anti-oxidant, whose uncommon thiol-thione resonance structure means that it is especially resistant to autoxidation. The discovery (and importance) of the ERG transporter SLC22A4 implies that although ERG is not made by mammals it is very important to both human and animal physiology.
Pre-eclampsia is a syndrome that is classically accompanied by oxidative stress. Previous attempts to relieve this using ascorbate may have floundered because the presence of unliganded iron turns it into a pro-oxidant [21, 24] ; ERG does not suffer from this problem. Consequently, it is considered reasonable, and we adduce the evidence here, that ERG might be protective in pregnancies considered at risk of being accompanied by pre-eclampsia. As a natural compound widely sold as a health supplement, and with an apparently excellent safety record, it holds out a significant opportunity to become a useful substance for the potential prevention and treatment of pre-eclampsia.
Future perspectives
Given its favourable safety profile and multiple mechanisms of action, the anti-oxidant ERG clearly has the potential for multiple clinical applications that might usefully be explored across a wide variety of pathologies involving oxidative stress, and not just in pre-eclampsia on which we have focussed here. Our group are currently testing the efficacy of ERG in a rodent model of pre-eclampsia. In terms of the mechanism of protective action in pre-eclampsia, the role of iron chelation and an assessment of the specific anti-oxidant pathways activated by ERG in pre-eclampsia are those aspects that most require further investigation. Overall, the compound's long half-life, resistance to autoxidation and to any pro-oxidant activity, as well as its presently negligible side effect profile, suggests it could transition to the clinic and even (as a nutraceutical) to the home in the future as a potential prenatal preventive or treatment for both pre-eclampsia and for other inflammatory diseases.
